{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-TTLDQECV/6448af59-7df9-4e0b-aed3-fc17a7b9c503/PDF","dcterms:extent":"1112 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-TTLDQECV/6da0c31e-20dd-4b87-83c3-2b01fc8dcc64/TEXT","dcterms:extent":"34 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-TTLDQECV","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2024","dc:creator":"Perišić, Milica","dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:75"},{"@xml:lang":"sl","#text":"str. 26-33"}],"dc:identifier":["COBISSID_HOST:197436163","ISSN:2536-4316","URN:URN:NBN:SI:doc-TTLDQECV"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Antigeni"},{"@xml:lang":"en","#text":"cancer immunotherapy"},{"@xml:lang":"sl","#text":"Cepiva proti raku"},{"@xml:lang":"sl","#text":"Imunoterapija"},{"@xml:lang":"sl","#text":"imunoterapija raka"},{"@xml:lang":"sl","#text":"Klinične raziskave"},{"@xml:lang":"en","#text":"tumor associated antigens"},{"@xml:lang":"sl","#text":"tumorji, povezani z antigeni"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Cepiva za preprečevanje razvoja in zdravljenje rakavih bolezni| razvojne platforme in trenutni napredek| Prophylactic and therapeutic cancer vaccines| development platforms and current progress|"},"dc:description":[{"@xml:lang":"sl","#text":"Vaccines are medicines that train the immune system to find and destroy harmful germs and cells. Vaccinations we receive throughout the life prevent common bacterial and virus illnesses. In addition, there are vaccines to prevent or treat certain types of cancer. Preventive cancer vaccines have proven successful in reducing the incidence of several cancers that are induced by viral infections. Therapeutic vaccines are immunotherapeutics that guide and boost the immune system to fight cancer. Unlike prophylactic vaccines that target viruses, therapeutic vaccines target cancer cells that closely resemble normal, healthy cells, making their development more difficult. In this review new developments in the field of cancer vaccines, success of prophylactic vaccines and challenges in the development of therapeutic cancer vaccines will be discussed"},{"@xml:lang":"sl","#text":"Cepiva so zdravila, ki imunski sistem pripravijo na to, da najde in uniči škodljive mikroorganizme in celice. Cepimo se v vseh življenjskih obdobjih, da se zaščitimo pred nalezljivimi boleznimi, ki jih po - vzročajo bakterije ali virusi. Obstajajo tudi cepiva proti raku, tako cepiva za preprečevanje raka kot cepiva za zdravljenje raka. Cepiva za preprečevanje raka nas ščitijo pred virusnimi okužbami, ki lahko izzovejo (pred)rakave spremembe. Cepiva za zdravljenje raka ali terapevtska cepiva so imunoterapevtiki, ki usmerijo in okrepijo imunski sistem za boj proti raku. Za razliko od preventivnih cepiv, ki ščitijo pred virusi, cepiva za zdravljenje raka ščitijo pred rakavimi celicami, ki so bolj podobne zdravim celicam, zaradi česar je razvoj teh cepiv težji. V preglednem članku razpravljamo o novostih na področju cepiv proti raku, o uspehu cepiv za preprečevanje raka in izzivih pri razvoju cepiv za zdravljenje raka"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-TTLDQECV","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-TTLDQECV"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-TTLDQECV/6448af59-7df9-4e0b-aed3-fc17a7b9c503/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-TTLDQECV/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-TTLDQECV"}}}}